PL1602647T3 - Nowy związek zawierający jako podstawnik grupę 4-pirydyloalkilotio - Google Patents

Nowy związek zawierający jako podstawnik grupę 4-pirydyloalkilotio

Info

Publication number
PL1602647T3
PL1602647T3 PL04717833T PL04717833T PL1602647T3 PL 1602647 T3 PL1602647 T3 PL 1602647T3 PL 04717833 T PL04717833 T PL 04717833T PL 04717833 T PL04717833 T PL 04717833T PL 1602647 T3 PL1602647 T3 PL 1602647T3
Authority
PL
Poland
Prior art keywords
substituent
novel compound
pyridylalkylthio group
pyridylalkylthio
group
Prior art date
Application number
PL04717833T
Other languages
English (en)
Inventor
Takahiro Honda
Hisashi Tajima
Yoshimasa Sasabuchi
Kenji Kawashima
Kazuyoshi Okamoto
Minoru Yamamoto
Masakazu Ban
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of PL1602647T3 publication Critical patent/PL1602647T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/32—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
PL04717833T 2003-03-07 2004-03-05 Nowy związek zawierający jako podstawnik grupę 4-pirydyloalkilotio PL1602647T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003062042 2003-03-07
JP2004011602 2004-01-20
PCT/JP2004/002812 WO2004078723A1 (ja) 2003-03-07 2004-03-05 ４－ピリジルアルキルチオ基を置換基として有する新規化合物
EP04717833.0A EP1602647B1 (en) 2003-03-07 2004-03-05 Novel compound having 4-pyridylalkylthio group as substituent

Publications (1)

Publication Number Publication Date
PL1602647T3 true PL1602647T3 (pl) 2014-05-30

Family

ID=32964918

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04717833T PL1602647T3 (pl) 2003-03-07 2004-03-05 Nowy związek zawierający jako podstawnik grupę 4-pirydyloalkilotio

Country Status (7)

Country Link
US (3) US7534802B2 (pl)
EP (2) EP2527326B1 (pl)
JP (1) JP5183647B2 (pl)
ES (2) ES2441176T3 (pl)
PL (1) PL1602647T3 (pl)
TW (2) TWI422583B (pl)
WO (1) WO2004078723A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078723A1 (ja) 2003-03-07 2004-09-16 Santen Pharmaceutical Co. Ltd. ４－ピリジルアルキルチオ基を置換基として有する新規化合物
ES2368153T3 (es) * 2004-02-17 2011-11-14 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que presenta un grupo 4-piridilalquiltio que presenta amino (no) sustituido introducido en el mismo.
ATE512950T1 (de) 2004-02-17 2011-07-15 Santen Pharmaceutical Co Ltd Neue cyclische verbindung mit 4- pyridylalkylthiogruppe mit darin eingeführtem (un)substituiertem amino
ES2351613T3 (es) 2005-03-03 2011-02-08 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que tiene un grupo quinolilalquiltio.
JP4585978B2 (ja) * 2005-03-03 2010-11-24 参天製薬株式会社 キノリルアルキルチオ基を有する新規環式化合物
JP4834441B2 (ja) * 2005-03-31 2011-12-14 参天製薬株式会社 ピリミジニルアルキルチオ基を有する新規環式化合物
ES2548729T3 (es) 2005-03-31 2015-10-20 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que tiene grupo pirimidinilalquiltio
JP5216341B2 (ja) 2007-01-29 2013-06-19 参天製薬株式会社 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体
AR066379A1 (es) * 2007-05-02 2009-08-12 Boehringer Ingelheim Int Amidas de acido carboxilico su preparacion y su uso como medicamentos
EP2460787A1 (en) * 2007-07-03 2012-06-06 Astellas Pharma Inc. Amide compounds and their use as PGE2 antagonists.
US8598355B2 (en) 2008-05-14 2013-12-03 Astellas Pharma Inc. Amide compound
PT3252057T (pt) 2009-12-04 2024-06-04 Sunovion Pharmaceuticals Inc Compostos multicíclicos e métodos de utilização dos mesmos
MX2019000982A (es) 2016-07-29 2019-07-04 Sunovion Pharmaceuticals Inc Compuestos y composiciones y usos de los mismos.
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
CN116808023A (zh) 2017-02-16 2023-09-29 桑诺维恩药品公司 治疗精神分裂症的方法
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
MX2020008537A (es) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Sales, formas cristalinas y metodos de produccion de las mismas.
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
CN114450274A (zh) 2019-07-11 2022-05-06 伊斯凯普生物公司 作为lrrk2抑制剂的吲唑及氮杂吲唑
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
CR20250118A (es) * 2022-09-09 2025-08-27 Latigo Biotherapeutics Inc Compuestos bloqueadores del canal de sodio, derivados de los mismos y métodos de su uso

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE455684B (sv) 1986-12-11 1988-08-01 Sunds Defibrator Anordning for kontinuerlig vegning av en fiberbana vid framstellning av fiberboard
EP0362239B1 (de) 1987-05-22 1993-03-10 General Engineering (Netherlands) B.V. Klemmvorrichtung für das gurtband von kraftfahrzeugsicherheitsgurten
US4970224A (en) * 1988-04-15 1990-11-13 Rohm And Haas Company 1-dimethylcarbamoyl-3-substituted-5-substituted-1H-1,2,4-triazzoles
JPH02129173A (ja) * 1988-11-10 1990-05-17 Ishihara Sangyo Kaisha Ltd トリアゾール系化合物、それらの製造方法及びそれらを含有する有害生物防除剤
DE3929673A1 (de) * 1989-09-07 1991-03-14 Bayer Ag Substituierte carbamoyltriazole
JP2501051B2 (ja) 1991-09-30 1996-05-29 バンドー化学株式会社 搬送用ベルトの製造方法
WO1997030035A1 (en) 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
CA2289102A1 (en) 1997-05-07 1998-11-12 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
JP3500401B2 (ja) 1998-12-25 2004-02-23 譲治 田中 介護用電動歯ブラシ器
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
RS50504A (sr) * 2001-11-08 2007-04-10 Elan Pharmaceuticals Inc., Derivati n,n'-supstituisanog-1,3- diamino-2-hidroksipropana
US20050113450A1 (en) * 2002-08-23 2005-05-26 Atli Thorarensen Antibacterial agents
US20040110802A1 (en) * 2002-08-23 2004-06-10 Atli Thorarensen Antibacterial benzoic acid derivatives
WO2004078723A1 (ja) 2003-03-07 2004-09-16 Santen Pharmaceutical Co. Ltd. ４－ピリジルアルキルチオ基を置換基として有する新規化合物
HUP0304101A3 (en) * 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
ATE512950T1 (de) 2004-02-17 2011-07-15 Santen Pharmaceutical Co Ltd Neue cyclische verbindung mit 4- pyridylalkylthiogruppe mit darin eingeführtem (un)substituiertem amino

Also Published As

Publication number Publication date
US20060194836A1 (en) 2006-08-31
EP1602647A4 (en) 2009-07-01
JP2010116403A (ja) 2010-05-27
JP5183647B2 (ja) 2013-04-17
ES2441176T3 (es) 2014-02-03
TWI369353B (en) 2012-08-01
EP2527326A1 (en) 2012-11-28
EP1602647A1 (en) 2005-12-07
EP2527326B1 (en) 2014-10-08
WO2004078723A1 (ja) 2004-09-16
US7534802B2 (en) 2009-05-19
TWI422583B (zh) 2014-01-11
US8207194B2 (en) 2012-06-26
ES2527185T3 (es) 2015-01-21
EP1602647B1 (en) 2013-10-16
US8518973B2 (en) 2013-08-27
US20120202817A1 (en) 2012-08-09
TW200510377A (en) 2005-03-16
TW201040159A (en) 2010-11-16
US20090286786A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
IL174375A0 (en) Novel heterocyclic compounds as hsp90-inhibitors
TWI369353B (en) Novel compound having 4-pyridylalkylthio group as substituent
GB0304424D0 (en) Novel compounds
GB0305927D0 (en) Compound
GB0306718D0 (en) Compound
EP1596860A4 (en) NEW CONNECTIONS
GB0324792D0 (en) Compound
GB0322629D0 (en) Novel compound
EP1648885A4 (en) NEW CONNECTIONS
GB0313677D0 (en) Novel compound
GB0317841D0 (en) Compound
GB0317842D0 (en) Compound
GB0302546D0 (en) Novel compounds
GB0304809D0 (en) Novel compounds
GB0302431D0 (en) Novel compounds
GB0324599D0 (en) Compound
GB0327738D0 (en) Novel compound
AU2003244179A8 (en) Novel chromene compound
GB0316107D0 (en) Compound
GB0318347D0 (en) Compound
GB0306717D0 (en) Compound
GB0330013D0 (en) Compound
GB0315885D0 (en) Compound
GB0300714D0 (en) Compound
GB0328509D0 (en) Compound